After Real-World Data Row, AZ Looks To NHS England For Tagrisso Deal
NICE Rejected Real World Data
Executive SummaryTagrisso has become AstraZeneca’s oncology flagship product, but cannot secure frontline use in England.
You may also be interested in...
Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.
Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.